Market Size of Global Stroke Therapeutics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Stroke Therapeutics Market Analysis
The stroke therapeutics market is projected to register a CAGR of 4.5% during the forecast period, 2022-2027.
Due to the presence of a huge stroke patient base across the world, there is a need for innovative and safe stroke treatment. Currently, only Tissue Plasminogen Activators (TPA) therapy is approved for stroke treatment. Additionally, surgery and removing clots by using a stent retriever are some of the other options available to recover from the stroke. Anti-platelets, anti-coagulants, and anti-convulsant are utilized for the further management of stroke. Covid-19 has significantly impacted the overall healthcare industry. Though it does not directly impact the stroke therapy market, however, there was a disruption in the supply chain of diagnostic & treatment devices and therapeutics. Additionally, many industry players reduced their investment in further development of innovative therapy due to financial losses during the Covid-19 period.
There is a huge population with high cholesterol, high blood pressure, obesity, diabetes, and cardiovascular diseases due to a sedentary lifestyle, and these are the key risk factors for stroke. According to data published by World Stroke Organization (WSO) in 2022, About 12 million (12,224,551) people experienced a stroke in 2019. The organization stated that there are more than 12.2 million new strokes each year, and globally, one in four people after 25 years of age experience a stroke in their lifetime. Hence, the increasing burden of patients globally is expected to drive market growth.
Patent expiry of branded drugs in recent years may impede the therapeutics market growth. For instance, Xarelto's (Rivaroxaban) US7585860 patent expired in December 2020, and the US7585860 patent is expected to expire by June 2022. Already, Breckenridge, Aurobindo, Hec Pharma, Invagen, Mylan, SigmaPharma, Microlabs, Torrent, Sun (Taro), Teva, Prinston Pharma, Alembic, Macleods, Lupin, and Accord (Intas) filed Abbreviated New Drug Application (ANDA) for the same drug. Hence, the entry of several generic is likely to increase pricing pressure on the market players, and this factor may hamper the market growth.
Stroke Therapeutics Industry Segmentation
As per the scope of this report, stroke is a condition in which the supply of blood is reduced or blocked completely to the brain, and this is either due to clots or rupturing of the blood vessel in the brain. The stroke therapeutics market is segmented by Type (Ischemic Stroke, Hemorrhagic Stroke), By Treatment (Tissue Plasminogen Activators (TPA), Anticoagulants, Antiplatelets, Others), By End User (Hospitals, Clinics, Others), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.
| By Type | |
| Ischemic Stroke | |
| Hemorrhagic Stroke |
| By Treatment | |
| Tissue Plasminogen Activators (TPA) | |
| Anticoagulants | |
| Antiplatelets | |
| Others |
| By End User | |
| Hospitals | |
| Clinics | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Stroke Therapeutics Market Size Summary
The stroke therapeutics market is experiencing a steady growth trajectory, driven by the increasing global prevalence of stroke and the need for innovative treatment solutions. The market is characterized by a reliance on Tissue Plasminogen Activators (TPA) as a primary treatment option, alongside surgical interventions and the use of anti-platelets, anti-coagulants, and anti-convulsants for ongoing management. The market's expansion is supported by the rising incidence of risk factors such as high cholesterol, hypertension, obesity, diabetes, and cardiovascular diseases, which are prevalent due to sedentary lifestyles. Despite the challenges posed by the COVID-19 pandemic, which disrupted supply chains and led to reduced investments in new therapies, the market continues to grow, bolstered by awareness programs and advancements in healthcare access, particularly in developing regions.
North America, with the United States at its forefront, dominates the stroke therapeutics market due to its advanced healthcare infrastructure and rapid access to treatment. The region's leadership is expected to continue, driven by the development of innovative therapies and the presence of major industry players. The market is competitive and fragmented, with patent expiries leading to the entry of generics, intensifying competition among key players such as AstraZeneca, Bayer AG, and Pfizer Inc. Recent advancements, including the approval of new drugs and the exploration of robotic and mini-organ therapies, highlight the ongoing innovation within the sector. However, the market faces challenges from patent expiries and the introduction of clot-retrieval devices, which may impact the growth of TPA-based treatments.
Global Stroke Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Investment by Market Players for the Development of New Therapy and Advanced Technology
-
1.2.2 Increasing Number of Stroke Patients
-
-
1.3 Market Restraints
-
1.3.1 Entry of Various Generic Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Type
-
2.1.1 Ischemic Stroke
-
2.1.2 Hemorrhagic Stroke
-
-
2.2 By Treatment
-
2.2.1 Tissue Plasminogen Activators (TPA)
-
2.2.2 Anticoagulants
-
2.2.3 Antiplatelets
-
2.2.4 Others
-
-
2.3 By End User
-
2.3.1 Hospitals
-
2.3.2 Clinics
-
2.3.3 Others
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Global Stroke Therapeutics Market Size FAQs
What is the current Global Stroke Therapeutics Market size?
The Global Stroke Therapeutics Market is projected to register a CAGR of 4.5% during the forecast period (2024-2029)
Who are the key players in Global Stroke Therapeutics Market?
Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, F. Hoffmann La Roche Ltd., Johnson & Johnson and Pfizer Inc are the major companies operating in the Global Stroke Therapeutics Market.
